In recent years, there has been a rapid uptake in the use of laparoscopic and robotic surgery within urological oncological surgery. There is now growing interest in applying these surgical techniques to functional and reconstructive urology (FRU).
In the literature there are conflicting conclusions for Radical Prostatectomy (RP) after previous surgery for benign prostatic hyperplasia (BPH). The advent of Robotic-Assisted Radical Prostatectomy (RARP) has allowed technical advances in preservation and reconstruction of the anatomical structures.
Purpose: Robot-assisted radical cystectomy (RARC) is known to have less postoperative morbidity and complications than open radical cystectomy. However, various complications not yet have been reported after RARC.
For those of us who take care of patients with the sixth most common malignancy in the United States and the seventh most common cause of cancer-related death,1 it was disheartening that, as recently as 2015, patients with advanced bladder cancer had no effective alternatives to cisplatinum-based chemotherapy, a status quo that had persisted for three […]
Recent years have seen an explosive rate of transformative advances in both pre-clinical and clinical urothelial carcinoma research. With the public dissemination of comprehensive molecular data from The Cancer Genome Atlas (TCGA) urothelial carcinoma cohort, the global urothelial carcinoma research community now has the initial road map of the key biological themes that drive carcinogenesis, growth, […]
San Francisco, CA (UroToday.com) — A newly available drug may improve the effectiveness of immunotherapy in hard-to-treat cancers of the upper urinary tract, suggests a study published by Weill Cornell Medicine and NewYork-Presbyterian investigators.For the study, published July 5 in Nature Communications, the research team set out to learn more about the biological characteristics of upper […]
San Francisco, CA (UroToday.com) — TARIS Bio™, a biopharmaceutical company developing transformational therapies to treat people with debilitating urological disorders, announced positive safety, tolerability and preliminary efficacy data from the full patient cohort (n=20) of its Phase 1b study of TAR-200 for the treatment of patients with muscle invasive bladder cancer (MIBC), neoadjuvant to radical […]
A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy Condition: Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B, Bladder Cancer TNM Staging Primary […]
The aim of the present study was to identify and test a urine marker panel of genes involved in DNA methylation and histone modification for the detection of urothelial carcinoma of the bladder (UCB). RNA samples obtained from the voided urine of 227 patients with asymptomatic microscopic haematuria (AMH) were analysed. Gene array analysis was […]
The “gold standard” diagnostic procedure for bladder cancer is cystoscopy, a technique that can be invasive, expensive, and a possible cause of urinary tract infection. Unlike techniques such as histology, PCR, and staining, assays for protein biomarkers lend themselves well to the creation of efficient point-of-care tests, which are easy to use and yield fast […]
